Servier to Present Glioma Data at SNO Annual Meeting

BOSTON, Nov. 6, 2026 /CourierPR/ -- Servier, a global leader in oncology, is set to present nine abstracts, including five oral presentations, at the 31st Society for Neuro-Oncology (SNO) Annual Meeting, November 12-15 in Philadelphia. The data span the company's growing glioma portfolio and include clinical and real-world data for VORANIGO® (vorasidenib) in IDH-mutant glioma, as well as recently released four-year data from the Phase 2 FIREFLY-1 study of OJEMDA® (tovorafenib) in relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG).

The FIREFLY-1 study, which has been followed up for four years, will be presented in an oral presentation. The study provides additional information on the duration of response to OJEMDA® in patients with relapsed or refractory BRAF-altered pLGG. The data will include information on post-treatment observation and retreatment with OJEMDA following disease progression in these patients.

Two oral presentations will feature analyses from the Phase 3 INDIGO trial, which have extended follow-up data (median overall duration of 41.6 months) from patients with Grade 2 IDH-mutant glioma randomized to receive VORANIGO. The results demonstrate sustained, long-term clinical benefits of VORANIGO in Grade 2 IDH-mutant glioma regardless of prognostic factors. A separate analysis suggests that long-term treatment with VORANIGO generally led to a sustained decrease in seizure activity and delayed worsening of quality of life in patients with IDH-mutant glioma.

Two oral presentations will highlight retrospective observational analyses of real-world utilization of VORANIGO in Grade 2 and Grade 3 IDH-mutant glioma. The analyses of time to next intervention (TTNI) among 499 patients with Grade 2 IDH-mutant glioma demonstrated short-term real-world effectiveness of VORANIGO. The highest rate was observed among frontline VORANIGO users. An analysis of a cohort of 80 Grade 3 mIDH glioma patients showed emerging evidence of the effectiveness of VORANIGO in these patients.

Servier's commitment to advancing targeted therapies for adults and children living with significant unmet needs is underscored by the breadth of clinical and real-world data presented. The company invests close to 20% of revenue from brand-name medicines in R&D each year, with a focus on identifying mutations and understanding how these mutations impact cancer and its progression.

Gliomas are tumors that arise from glial or precursor cells within the central nervous system (CNS). The 2021 World Health Organization (WHO) classification recognizes four general groups of gliomas, one of which is adult-type diffuse gliomas. These diffuse gliomas are the most common primary malignant brain tumors in adults. The pathogenesis and prognosis of these tumors are tightly linked to mutations (or lack thereof) in the metabolic enzyme isocitrate dehydrogenase (IDH), and molecular testing is required for proper diagnosis.

Pediatric low-grade gliomas (pLGG) are the most common brain tumor with an estimated US incidence of 1,100 and Europe incidence of 700 children per year who are eligible for front-line systemic therapy. BRAF is the gene most commonly altered in pLGG, which includes two primary types of BRAF alterations, a BRAF gene fusion and BRAF point mutation. These BRAF alterations account for more than 50% of pLGG cases worldwide, and prior to the introduction of OJEMDA, there were no approved treatments for people with pLGG driven by BRAF fusions.

OJEMDA® is a prescription medicine used to treat a type of brain tumor (cancer) called pediatric low-grade glioma (pLGG) in people 6 months of age and older whose tumor has come back after previous treatment or did not respond to previous treatment, and that has a certain type of abnormal BRAF gene. A healthcare provider will perform a test to confirm that OJEMDA is right for the patient. VORANIGO® is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery. Your healthcare provider will perform a test to make sure that VORANIGO is right for you.